There’s only one approved CAR-T, but companies are ready to capitalize on it – STAT
STAT |
There's only one approved CAR–T, but companies are ready to capitalize on it
STAT AR-T is having a moment. Novartis (NVS 1) won the first Food and Drug Administration approval 2 in August for this class of personalized cancer treatments, beating rivals in the race 3 to sell a therapy that is custom-made with individual patients' cells. |
